Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Cervical Cancer
NCT06426056Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Cervical Cancer (CC), sponsored by Peking University Third Hospital. Primary endpoint: Objective Response Rate at 12 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06426056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06426056.